PURPOSE: To report the long-term follow-up of a cohort of adult patients with supratentorial low-grade glioma treated at a single institution. METHODS AND MATERIALS: A cohort of 145 adult patients treated at the London Regional Cancer Program between 1979 and 1995 was reviewed. RESULTS: With a median follow-up of 105 months, the median progression-free survival was 61 months (95% confidence interval, 53-77), and the median overall survival was 118 months (95% confidence interval, 93-129). The 10- and 20-year progression-free and overall survival rate was 18% and 0% and 48% and 22%, respectively. Cox regression analysis confirmed the importance of age, histologic type, presence of seizures, Karnofsky performance status, and initial extent of surgery as prognostic variables for overall and cause-specific survival. Function among long-term survivors without tumor progression was good to excellent for most patients. CONCLUSION: Low-grade glioma is a chronic disease, with most patients dying of their disease. However, long-term survival with good function is possible. Survival is determined primarily by the disease factors with selection and timing of adjuvant treatments having less influence on outcome.
PURPOSE: To report the long-term follow-up of a cohort of adult patients with supratentorial low-grade glioma treated at a single institution. METHODS AND MATERIALS: A cohort of 145 adult patients treated at the London Regional Cancer Program between 1979 and 1995 was reviewed. RESULTS: With a median follow-up of 105 months, the median progression-free survival was 61 months (95% confidence interval, 53-77), and the median overall survival was 118 months (95% confidence interval, 93-129). The 10- and 20-year progression-free and overall survival rate was 18% and 0% and 48% and 22%, respectively. Cox regression analysis confirmed the importance of age, histologic type, presence of seizures, Karnofsky performance status, and initial extent of surgery as prognostic variables for overall and cause-specific survival. Function among long-term survivors without tumor progression was good to excellent for most patients. CONCLUSION: Low-grade glioma is a chronic disease, with most patients dying of their disease. However, long-term survival with good function is possible. Survival is determined primarily by the disease factors with selection and timing of adjuvant treatments having less influence on outcome.
Authors: A Hallock; B Hamilton; L C Ang; K Y Tay; J F Meygesi; B J Fisher; C J Watling; D R Macdonald; G S Bauman Journal: Neuro Oncol Date: 2011-08-08 Impact factor: 12.300
Authors: Marthe C M Peeters; Linda Dirven; Johan A F Koekkoek; Ellen G Gortmaker; Lara Fritz; Maaike J Vos; Martin J B Taphoorn Journal: J Neurooncol Date: 2020-01-01 Impact factor: 4.130